

Supplemental Table 1. Baseline Demographic and Clinical Parameters

	Flare (n = 28)	NF (n = 28)
Average Age (\pm SD)	46.9 (14.0)	47.2 (12.3)
Median Age at Diagnosis	39.5	41.0
Average Number of ACR Criteria	5.5	5.0
Baseline Average SELENA-SLEDAI (\pm SD) ^a	3.8 (3.7)	2.6 (3.2)
Baseline Average ESR (\pm SD) ^b	25.5 (21.3)	16.8 (9.6)
Medications (Number of SLE patients treated)		
• Prednisone	11	8
• Immunosuppressants ^c	12	10
• Anti-malarials ^d	21	21
• Biologics ^e	2	2
	Flare (n = 13)	SNF (n = 13)
Baseline Average SELENA-SLEDAI (\pm SD) ^a	3.0 (4.3)	2.9 (2.0)
Baseline Average ESR (\pm SD) ^b	31.3 (23.0)	27.0 (21.4)
Medications (Number of SLE patients treated)		
• Prednisone	5	3
• Immunosuppressants ^c	7	8
• Anti-malarials ^d	10	9
• Biologics ^e	1	1

^a Flare vs NF $p = 0.2451$; Flare vs SNF $p = 0.7065$ by Wilcoxon matched-pairs test

^b Flare vs NF $p = 0.0870$; Flare vs SNF $p = 0.5967$ by Wilcoxon matched-pairs test

^c azathioprine, mycophenolate mofetil, or methotrexate

^d hydroxychloroquine or quinacrine


^e infliximab or etanercept

Supplemental Table 2. Soluble mediators tested in SLE and control plasma


Innate	Th1-like	NGF/TNFR Superfamily
IL-1 α	IL-12 (p70)	BLyS*
IL-1 β	IFN- γ	APRIL*
IL-1RA	IL-2	sCD40L
IFN- α **	IL-2RA	sFas
IFN- β **		sFasL
G-CSF**	Th-17 like	TNF- α
	IL-17A	TNFR1 (p55)
Homeostasis	IL-21	TNFR2 (p75)
IL-7**	IL-23	TRAIL**
IL-15	IL-6	NGF β **
Other	Th2-like	Chemokine/Adhesion molecules
LIF**	IL-4**	IL-8/CXCL8
PAI-1**	IL-5	IP-10/CXCL10
PDGF-BB**	IL-13	RANTES/CCL5**
Resistin**		MIP-1 α /CCL3
Leptin	Regulatory	MIP-1 β /CCL4
SCF	IL-10	MCP-1/CCL2
	TGF- β	MCP-3/CCL7
		GRO α /CXCL1**
		SDF-1/CXCL12
		MIG/CXCL9
		Eotaxin/CCL11**
		ICAM-1
		VCAM-1**
		sE-selectin
		VEGF-A**

*assessed by ELISA

** no statistical difference between SLE patients and healthy controls



Supplementary Figure 1. Altered adaptive immunity and soluble TNF superfamily members in SLE patients with impending and concurrent disease flare. Plasma Th1 (A, IL-12p70, IFN-g, and IL-2), Th2 (B, IL-5, IL-13, and IL-6), and Th17 (C, IL-23p19, IL-17A, and IL-21) type cytokines, as well as chemokines (D, IP-10, MCP-1, and MCP-3), soluble TNF superfamily members (E, TNF- α , TNFR1, TNFR2, Fas, FasL, and CD40L), regulatory mediators (F, IL-10, TGF- β , SDF-1), IL-RA/IL-1 β balance (G, IL-1 β , IL-1RA, and ratio of IL-1RA:IL-1 β), and other inflammatory mediators (H, IL-1 α , IL-8, ICAM-1, SCF, RANTES, and Resistin) (mean \pm SEM) were measured (mean \pm SEM) by xMAP multiplex assay according to manufacturer protocol (Affymetrix, Santa Clara, CA) and read on a Bio-plex 200 reader (Bio-Rad, Hercules, CA). Samples were procured at baseline (BL)/pre-vaccination (circle) from 28 EA SLE patients who exhibited disease flare (black symbol) 6 to 12 weeks later (follow-up [FU], square) vs. age (\pm 5 years)/race/gender/time of sample procurement matched SLE patients who did not flare (NF, blue symbol) vs. age (\pm 5 years)/race/gender/time of sample procurement matched unrelated/unaffected healthy controls (HC, open symbol). Significance determined by Friedman test with Dunn's multiple comparison (Friedman test significance listed under each title). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$



Supplementary Figure 2. SLE patients with impending and concurrent disease flare have altered adaptive immunity and soluble TNF superfamily members compared to corresponding period of non-flare. Plasma Th1 (A, IL-12p70, IFN γ , and IL-2), Th2 (B, IL-5, IL-13, and IL-6), and Th17 (C, IL-23p19, IL-17A, and IL-21) type cytokines, as well as chemokines (D, IP-10, MCP-1, and MCP-3), soluble TNF superfamily members (E, TNF- α , TNFR1, TNFR2, Fas, FasL, and CD40L), regulatory mediators (F, IL-10, TGF- β , SDF-1), IL-RA/IL-1b balance (G, IL-1b, IL-1RA, and ratio of IL-1RA:IL-1b), and other inflammatory mediators (H, IL-1a, IL-8, ICAM-1, SCF, RANTES, and Resistin) (mean \pm SEM) were measured (mean \pm SEM) by xMAP multiplex assay according to manufacturer protocol (Affymetrix, Santa Clara, CA) and read on a Bio-plex 200 Luminex-type reader (Bio-Rad, Hercules, CA). Samples were procured at baseline (BL)/pre-vaccination (circle) from 13 EA SLE patients who exhibited disease flare (black symbol) 6-12 weeks later (follow-up [FU], square) vs. the *same* SLE patients in a separate influenza season when they did not exhibit disease flare post-vaccination (SNF, red symbol) vs. age (\pm 5 years)/race/gender/time of sample procurement matched unrelated/unaffected healthy controls (HC, open symbol). Significance determined by Friedman test with Dunn's multiple comparison (Friedman test significance listed under each title). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$